Qiagen N.V.

Jan 31, 2018

QIAGEN Reports Results for Fourth Quarter and Full-year 2017, Announces STAT-Dx Acquisition and New $200 Million Share Repurchase

Jan 31, 2018

QIAGEN Enters into Agreement to Acquire STAT-Dx, Plans to Launch a Next-Generation, Fully Integrated Multiplex Platform for Syndromic Disease Testing

Jan 23, 2018

QIAGEN Receives FDA Clearance for First-Ever JAK2 Test for Use in Diagnosis of Additional Myeloproliferative Neoplasms

Jan 18, 2018

QIAGEN N.V. to Report Fourth Quarter and Full Year of 2017 Results

Jan 08, 2018

QIAGEN adds to Growth Momentum in Next-Generation Sequencing with 2018 Plans for Significant Portfolio Enhancements

Jan 08, 2018

QIAGEN and DiaSorin Partner to Offer Fully Automated Tuberculosis Detection With QuantiFERON-TB Gold Plus Available on LIAISON Analyzer Systems

Dec 22, 2017

QIAGEN to Take Impairment on Deferred Tax Assets, Informs on Expected Impacts of New U.S. Tax Law and Other Changes in Global Tax Environment

Dec 08, 2017

QIAGEN to Transfer U.S. Listing of Global Shares to NYSE

Nov 14, 2017

QIAGEN's GeneReader NGS System Delivers Accuracy and Ease of Use for Clinical Research in Oncology

Oct 16, 2017

QIAGEN N.V. to Report Third Quarter and First Nine Months of 2017 Results

Oct 12, 2017

QIAGEN Bioinformatics and NGS Solutions Enable Genomic Breakthroughs

Oct 09, 2017

QIAGEN and CENTOGENE to Collaborate in Bioinformatics for Genetic Diseases

Oct 02, 2017

QIAGEN Achieves ISO Certification for State-of-the-art Quality in Forensics